ArticleiScience2022
Glycosyltransferase engineering and multi-glycosylation routes development facilitating synthesis of high-intensity sweetener mogrosides.
Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 38 citations in OpenAlex.
- Influence of Drying Temperature on Quality Characteristics and Drying Kinetics ofFoods (Basel, Switzerland) · 2026Article
- A review ofChinese herbal medicines · 2026Review
- Molecular characterization and structural basis of a promiscuous glycosyltransferase for β-(1,6) oligoglucoside chain glycosides biosynthesis.Plant biotechnology journal · 2025Article
- Biosynthesis and metabolic engineering of natural sweeteners.AMB Express · 2025Review
- Selection of Reference Genes inPlants (Basel, Switzerland) · 2024Article
- Structural insights into the catalytic selectivity of glycosyltransferase SgUGT94-289-3 towards mogrosides.Nature communications · 2024Article
- Plant endophytic fungi exhibit diverse biotransformation pathways of mogrosides and show great potential application in siamenoside I production.Bioresources and bioprocessing · 2024Article
- The sugar donor specificity of plant family 1 glycosyltransferases.Frontiers in bioengineering and biotechnology · 2024Review
- Inhibition of Uridine 5'-diphospho-glucuronosyltransferases A10 and B7 by vitamins: insights from in silico and in vitro studies.In silico pharmacology · 2024Article
- Enhancing the thermostability and activity of glycosyltransferase UGT76G1 via computational design.Communications chemistry · 2023Article
- Post-Ripening and Key Glycosyltransferase Catalysis to Promote Sweet Mogrosides Accumulation ofMolecules (Basel, Switzerland) · 2023Article
- Pharmacological Activities of Mogrol: Potential Phytochemical against Different Diseases.Life (Basel, Switzerland) · 2023Review
- Structure-function and engineering of plant UDP-glycosyltransferase.Computational and structural biotechnology journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mogrosides are widely served as natural zero-calorie sweeteners. To date, the biosynthesis of high-intensity sweetness mogrosides V from mogrol has not been achieved because of inefficient and uncontrollable multi-glycosylation process. To address this challenge, we reported three UDP-glycosyltransferases (UGTs) catalyzing the primary and branched glycosylation of mogrosides and increased the catalytic efficiency by 74-400-folds toward branched glycosylation using an activity-based sequence conservative analysis engineering strategy. The computational studies provided insights into the origin of improved catalytic activity. By virtue of UGT mutants, we provided regio- and bond-controllable multi-glycosylation routes, successfully facilitating sequential glycosylation of mogrol to three kinds of mogroside V in excellent yield of 91-99%. Meanwhile, the feasibility of the routes was confirmed in engineered yeasts. It suggested that the multi-glycosylation routes would be combined with mogrol synthetic pathway to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.